M&G has confirmed it has invested in Cambridge-based biotech firm, Nuclera.
The company will use the $42.5 million it has raised from investors to accelerate the development and commercialisation of its eProtein desktop bioprinter which enables protein printing in 24 hours, faster than using existing methods of protein synthesis.
The investment has been made by M&G’s Catalyst strategy, which is investing up to £5 billion into innovative privately-owned businesses working to create a more sustainable world.
The strategy which has three core focuses – climate, healthcare and inclusion – provided pre-IPO financing to both Vaccitech Ltd and Oxford Nanopore Technologies last year.
Niranjan Sirdeshpande, director of M&G’s Catalyst investment team, said: “The drug discovery process can be long and costly for pharmaceutical companies but this technology will potentially be transformational in research projects across many biotech industries.
“Nuclera’s technology will enable scientists to access proteins to research at an accelerated rate, improving efficiencies, as well as widening access to proteins for research.”
© 2022 funds europe
